73 related articles for article (PubMed ID: 15693021)
1. Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma.
Caruso DA; Orme LM; Amor GM; Neale AM; Radcliff FJ; Downie P; Tang ML; Ashley DM
Cancer; 2005 Mar; 103(6):1280-91. PubMed ID: 15693021
[TBL] [Abstract][Full Text] [Related]
2. A critical time window for leukapheresis product transportation to manufacture clinical-grade dendritic cells with optimal anti-tumor activities.
Wang W; Jiang J; Yang C; Meng X; Gao L; Yuan Y; Lei T; Ding P; Yin R; Li Q
Cytotherapy; 2024 Feb; 26(2):210-220. PubMed ID: 38127032
[TBL] [Abstract][Full Text] [Related]
3. A finite mixture survival model to characterize risk groups of neuroblastoma.
Hunsberger S; Albert PS; London WB
Stat Med; 2009 Apr; 28(8):1301-14. PubMed ID: 19184977
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I/II clinical trial in Belgium.
Van Genechten T; De Laere M; Van den Bossche J; Stein B; De Rycke K; Deschepper C; Hazes K; Peeters R; Couttenye MM; Van De Walle K; Roelant E; Maes S; Vanden Bossche S; Dekeyzer S; Huizing M; Caluwaert K; Nijs G; Cools N; Verlooy J; Norga K; Verhulst S; Anguille S; Berneman Z; Lion E
BMJ Open; 2024 Mar; 14(3):e077613. PubMed ID: 38503417
[TBL] [Abstract][Full Text] [Related]
5. Clinical benefit and safety associated with mRNA vaccines for advanced solid tumors: A meta-analysis.
Zhang TY; Xu H; Zheng XN; Xiong XY; Zhang SY; Yi XY; Li J; Wei Q; Ai JZ
MedComm (2020); 2023 Aug; 4(4):e286. PubMed ID: 37470066
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy associated central nervous system complications in primary brain tumors.
Mantica M; Drappatz J
Front Oncol; 2023; 13():1124198. PubMed ID: 36874119
[TBL] [Abstract][Full Text] [Related]
7. mRNA therapeutics in cancer immunotherapy.
Beck JD; Reidenbach D; Salomon N; Sahin U; Türeci Ö; Vormehr M; Kranz LM
Mol Cancer; 2021 Apr; 20(1):69. PubMed ID: 33858437
[TBL] [Abstract][Full Text] [Related]
8. Tumour immune landscape of paediatric high-grade gliomas.
Ross JL; Velazquez Vega J; Plant A; MacDonald TJ; Becher OJ; Hambardzumyan D
Brain; 2021 Oct; 144(9):2594-2609. PubMed ID: 33856022
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice.
Islam MA; Rice J; Reesor E; Zope H; Tao W; Lim M; Ding J; Chen Y; Aduluso D; Zetter BR; Farokhzad OC; Shi J
Biomaterials; 2021 Jan; 266():120431. PubMed ID: 33099060
[TBL] [Abstract][Full Text] [Related]
10. Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy.
Amon L; Hatscher L; Heger L; Dudziak D; Lehmann CHK
Pharmaceutics; 2020 Jul; 12(7):. PubMed ID: 32674488
[TBL] [Abstract][Full Text] [Related]
11. Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: Ready 'N Able to Improve Clinical Outcome?
Willemen Y; Versteven M; Peeters M; Berneman ZN; Smits ELJ
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32012714
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells-An Update.
Dörrie J; Schaft N; Schuler G; Schuler-Thurner B
Pharmaceutics; 2020 Jan; 12(2):. PubMed ID: 31979205
[TBL] [Abstract][Full Text] [Related]
13. Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells.
Kyte JA; Aamdal S; Dueland S; Sæbøe-Larsen S; Inderberg EM; Madsbu UE; Skovlund E; Gaudernack G; Kvalheim G
Oncoimmunology; 2016; 5(11):e1232237. PubMed ID: 27999747
[TBL] [Abstract][Full Text] [Related]
14. Targeted immunotherapy for pediatric solid tumors.
Kopp LM; Katsanis E
Oncoimmunology; 2016 Mar; 5(3):e1087637. PubMed ID: 27141344
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in pediatric malignancies: current status and future perspectives.
Capitini CM; Otto M; DeSantes KB; Sondel PM
Future Oncol; 2014; 10(9):1659-78. PubMed ID: 25145434
[TBL] [Abstract][Full Text] [Related]
16. Cellular immunotherapy for pediatric solid tumors.
Hegde M; Moll AJ; Byrd TT; Louis CU; Ahmed N
Cytotherapy; 2015 Jan; 17(1):3-17. PubMed ID: 25082406
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission.
Kushner BH; Cheung IY; Modak S; Kramer K; Ragupathi G; Cheung NK
Clin Cancer Res; 2014 Mar; 20(5):1375-82. PubMed ID: 24520094
[TBL] [Abstract][Full Text] [Related]
18. Neuroblastoma: developmental biology, cancer genomics and immunotherapy.
Cheung NK; Dyer MA
Nat Rev Cancer; 2013 Jun; 13(6):397-411. PubMed ID: 23702928
[TBL] [Abstract][Full Text] [Related]
19. RESEARCH ADVANCES IN NEUROBLASTOMA IMMUNOTHERAPY.
Booker LY; Ishola TA; Bowen KA; Chung DH
Curr Pediatr Rev; 2009 May; 5(2):112-117. PubMed ID: 23606822
[TBL] [Abstract][Full Text] [Related]
20. Early immunisation with dendritic cells after allogeneic bone marrow transplantation elicits graft vs tumour reactivity.
Gigi V; Stein J; Askenasy N; Yaniv I; Ash S
Br J Cancer; 2013 Mar; 108(5):1092-9. PubMed ID: 23511628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
